6
Oct
2026
Biotech Pharmaceutical Co., Ltd.
About Biotech Pharmaceutical Co., Ltd.
Certifications
-
GMP
Categories
Meet us at
-
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026stand 18G74
-
Country/Region:China
-
Founded:2000
-
On CPHI since:2026
-
Certificates:1
-
Employees:1000 - 4999
Company types
Primary activities
Products from Biotech Pharmaceutical Co., Ltd. (4)
-
Product Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片
• Large and fast-growing market – global sales reached 3.574 billion USD, with growth exceeding that of enzalutamide.
Only the originator (Janssen) is available in China; generic entry is expected to achieve rapid volume uptake.
Expanding patient pool – prostate cancer incidence is ... -
Product Axitinib Tablets / 阿昔替尼片
• Largest-selling drug in the global renal cancer market – global sales reached 978 million USD in 2024, with a 5-year CAGR of 12.7%.
The only approved first-line targeted-immunotherapy combination in China (with toripalimab), listed as Category IA recommendation in 2024 CSCO guidelines.
... -
Product Ebidetide Injection (JY09) / 益百得肽注射液
1.Has a half-life of up to 240 hours and is the first bi-weekly GLP-1 receptor agonist globally to enter Phase III, significantly improving patient compliance.2.Precisely regulates insulin secretion only when blood glucose is elevated, resulting in an extremely low risk of hypoglycemia.3.Incidence of ... -
Product Nimoutuzumab Injection
Our flagship product, Nimotuzumab, is a humanized anti‑EGFR monoclonal antibody. Since its launch in China in 2008, it has been approved for the treatment of nasopharyngeal carcinoma, pancreatic cancer, and head and neck tumors, demonstrating robust clinical efficacy and a favorable safety profile. Annual ...